Telmisartan is an angiotensin II receptor blocker (ARB) used to manage high blood pressure and protect the heart and kidneys. This article covers Telmisartan, available as a generic medication and marketed under brand names such as Micardis. In Hong Kong, Telmisartan is prescription-only and regulated by the Department of Health.
Telmisartan blocks the binding of angiotensin II to the AT 1 receptor on blood vessels and the adrenal gland. By preventing this interaction, the drug:
The onset of action occurs within a few hours, with peak blood-pressure reduction typically seen after 2-3 hours. Telmisartan’s long half-life of approximately 24 hours supports once-daily dosing. It is well absorbed from the gastrointestinal tract, with an oral bioavailability of about 50 %, and is primarily excreted unchanged in the bile.
Telmisartan is approved by the Hong Kong Department of Health for:
Clinical guidelines recommend Telmisartan as a first-line option for adults whose blood pressure is above target levels (≥140/90 mm Hg). It can be used as monotherapy or in combination with diuretics, calcium-channel blockers, or other ARBs when tighter control is needed.
Research supports several off-label applications of Telmisartan, though these are not approved by regulatory agencies in Hong Kong:
Off-label use requires medical supervision and individualized risk assessment.
Ideal candidates
Absolute contraindications
Relative contraindications
Special populations
Standard dosing: 40 mg tablet taken once daily.
For patients requiring a lower dose, 20 mg may be prescribed.
In resistant hypertension, doses up to 80 mg daily are acceptable.
Administration: Swallow the pill whole with or without food. Do not crush or chew.
Missed dose: Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose; do not double up.
Overdose: Symptoms may include severe hypotension, dizziness, and fainting. Seek emergency medical care; treatment is primarily supportive.
Discontinuation: Telmisartan can be stopped abruptly, but a physician may advise tapering in patients with unstable blood pressure.
This article provides educational information about Telmisartan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Telmisartan can be combined with diuretics, calcium-channel blockers, or other antihypertensives to achieve better blood-pressure control. The combination should be prescribed by a clinician who will monitor for additive effects such as excessive lowering of blood pressure or electrolyte disturbances.
Take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with the regular dosing time. Adjusting the schedule should be done under medical guidance to avoid double dosing.
Telmisartan does not typically interfere with standard blood-test assays. However, because it can raise potassium levels, clinicians may request specific electrolyte panels to monitor for hyperkalemia.
Generic Telmisartan tablets may vary in size, shape, color, and imprint code depending on the manufacturer. All meet the same bioequivalence standards, but patients should verify the imprint with their pharmacist to ensure they have the correct medication.
Telmisartan does not directly affect uric acid metabolism. It can be safely prescribed to gout patients, but clinicians should monitor renal function and potassium, especially if the patient is on other medications that influence these parameters.
In patients receiving dialysis, Telmisartan can be used, but dose adjustments are often unnecessary because the drug is primarily excreted via bile. Nevertheless, clinicians should monitor blood pressure and electrolytes closely.
Both ARBs and ACE inhibitors reduce cardiovascular risk, but ARBs such as Telmisartan are less likely to cause cough or angio-edema. Clinical trials have shown comparable efficacy in preventing major cardiovascular events, though individual response varies.
A high-salt intake can counteract the blood-pressure-lowering effect of Telmisartan by increasing fluid retention. Patients are advised to follow a low-sodium diet (≤2 g of sodium per day) to maximize therapeutic benefits.
Mild to moderate hepatic impairment does not require dose reduction, but severe liver disease (Child-Pugh C) warrants careful assessment. Monitoring liver enzymes and renal function is recommended.
Telmisartan is not a prohibited substance under the World Anti-Doping Agency (WADA) regulations and typically does not appear in standard narcotic or performance-enhancing drug panels. However, athletes should always disclose all prescribed medications to their medical team.
